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Evidence for a role of PTH in the reduced pressor response to
norepinephrine in chronic renal failure. Reduced pressor response to
norepinephrine (NE) is present in patients with chronic renal failure
(CRF) and is responsible partly for some of the manifestations of
autonomic nervous system dysfunction in these patients. PTH blunts
the pressor response to NE in normal rats, suggesting that excess PTH
in CRF may be responsible for this abnormality. However, the relative
roles of uremia and of excess PTH in the uremic state in the genesis of
this abnormality are not defined. The present study examines this
question. Rats with chronic renal failure display reduced pressor
response to NE administration, but this derangement can be prevented
by prior parathyroidectomy and abolished by administration of indo-
methacin. The role of PTH in the genesis of this abnormality can also be
demonstrated in the hind limb preparation obtained from rats with CRF.
Our data show that excess PTH and not other consequences of CRF
plays a paramount pathogenetic role in the reduced pressor response to
NE and that this effect of PTH is due to a direct action on the blood
vessels. Further, this hormone action is most likely mediated through
increased production of vasodilating prostaglandins. These observa-
tions are constant with the idea that PTH would contribute to the
pathogenesis of some of the manifestations of autonomic nervous
system dysfunction in CRF.
Preuve d'un role de Ia PTH dans Ia reduction de Ia réponse pressive a
Ia noradrenaline au cours de l'insuffisance rénale chronique. Une réponse
pressive diminuée a Ia noradrénaline (NE) est presente chez des
malades en insuffisance rénale chronique (CRF) et est responsable
partiellemet de quelques unes des manifestations de dysfonctionnement
nerveux autonome chez ces malades. La PTH gene la réponse pressive
a Ia NE chez les rats normaux, ce qui suggère que l'excès de PTH au
cours de CRF pourrait être responsable de cette anomalie. Cependant,
les roles relatifs de l'urémie et de l'excès de PTH lors de l'urémie dans
la génése de cette anomalie ne sont pas définis. Cette étude a examine
cette question. Des rats en insuffisance rénale chronique présentaient
une reponse pressive réduite a I'administration de NE, et cette
anomalie était prevenue par une parathyroIdectomie préalable, et abolie
par l'administration d'indométhacine. Le rOle de Ia PTH dans Ia génèse
de cette anomalie a été aussi démontré sur une preparation de muscle de
Ia cuisse obtenue a partir de rats en CRF.
Nos données montrent que l'excès de PTH, et non les autres
consequences de CRF jouent un rOle pathogénique capital dans Ia
reduction de Ia réponse pressive a Ia NE. Cet effet de Ia PTH est dO a
une action directe sur les vaisseaux sanguins, cet effet hormonal est trés
probablement médié par une production de prostaglandines vasodilata-
trices. Ces observations sont compatibles avec Ia idée que Ia PTH
contribuerait fi Ia pathogénie de quelques unes des manifestations de
dysfonctionnement du système nerveux autonome lors de CRF.
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Available data indicate that parathyroid hormone (PTH) is a
vasodilator [1—31, and its excess blunts the pressor response to
vasoconstrictor agonists such as norepinephrine (NE) and
angiotensin II (All) [4, 5]. The latter effect is at least partly
mediated by PTH-induced production of prostaglandins [61.
Reduced responsiveness to NE is common in patients with
acute [7] and advanced chronic renal failure [8], and this
derangement underlies some of the manifestations of the auto-
nomic nervous system dysfunction in these patients [8]; more
specifically, this abnormality may be responsible for the greater
orthostatic hypotension in these patients [8]. Renal failure is
associated with secondary hyperparathyroidism and elevated
blood levels of PTH [9—12]. It is reasonable to suggest that the
excess PTH may be responsible for the reduced responsiveness
to vasoconstrictor agonists in patients with chronic renal failure
and plays a significant role in the pathogenesis of the autonomic
nervous system dysfunction in these patients.
However, there is no evidence that the response to NE is
normal in states of chronic renal failure in the absence of excess
PTH; and it is possible that consequences of uremia other than
secondary hyperparathyroidism also play a role in the reduced
pressor response to NE. The present study was undertaken to
examine the role of uremia with and without excess PTH in the
genesis of reduced pressor response to NE in rats with exper-
imental chronic renal failure.
Methods
Male Sprague-Dawley rats weighing 240 to 350 g were stud-
ied. They were fed normal Purina rat chow (ICN Nutritional
Biochemical, Cleveland, Ohio, USA) and housed in individual
cages. Parathyroidectomy (PTX) was performed in a group of
rats by electrocautery with the success of the procedure ascer-
tained by a decrease in plasma levels of calcium of at least 2
mgldl. The mean levels of plasma calcium 2 days after PTX was
7.3 0.21 mg/dl. These rats were allowed to drink water freely
containing 80 g/liter of calcium gluconate. This procedure is
adequate to normalize plasma levels of calcium in PTX rats.
Another group of rats underwent sham PTX. Seven days after
PTX or sham PTX procedures, the animals underwent a right
flank incision nephrectomy, and a week later partial left
nephrectomy was performed. Thus, this protocol provided two
groups of rats with chronic renal failure (CRF): one with intact
parathyroid glands (CRF-sham PTX) and the other without
parathyroid glands (CRF-PTX). The animals were maintained
11
12 Iseki et al
Table 1. Body weight, mean arterial pressure (MAP), heart rate, serum concentration of calcium and creatinine in control, CRF-sham PTX












Control 8 316 3.2 106 3.2 370 5.6 — 0.5 0.06
Control with
indomethacin 9 308 4.3 104 3.1 375 12.7 — 0.5 0.06
CRF-sham PTX 8 294 9.5 125 5.3° 394 14.0 10.9 0.81 1.6 0.11°
CRF-sham PTX with
indomethacin 8 307 12 111 5.2 388 17.3 9.4 0.47 1.4 0.11°
CRF-PTX 8 301 5.9 125 4.2a 403 15.5 9.1 0.39 1.4 0.11°
Abbreviations: N, number; CRF, chronic renal failure; PTX, parathyroidectomy. Data are presented as mean SE.
a Denotes significant difference from control rats with P < 0.01.
in a state of CRF for 14 days. The CRF-s ham PTX were divided
into two subgroups; on day 12 of CRF, one subgroup received
indomethacin, 3.3 mg/kg body wt, intraperitoneally every 8 hr
for 2 days while the other group received vehicle only. The
indomethacin was dissolved in normal saline which was made
alkaline (pH 8.0) by the addition of sodium bicarbonate. In the
rat, this dose of indomethacin has been shown to reduce urinary
excretion of PGE2 by more than 85% [131. In addition, normal
rats receiving indomethacin or vehicle, as described above,
were included in the study.
The pressor response to varying doses of NE was evaluated
in all animals (CRF-PTX, CRF-sham PTX with and without
indomethacin treatment, and normal rats with and without
indomethacin treatment). The rats were anesthetized with
intraperitoneal injection of 40 to 50 mg of sodium
pentobarbital/kg body wt (Western Medical Supply, Inc.,
Arcadia, California, USA). Through an incision on the ventral
surface of the neck, the left carotid and one or both jugular
veins were cannulated with polyethylene tubing (PE 50, Clay
Adams, Parsipany, New Jersey, USA), filled with solution of
sodium heparin (1000 IU/ml in 0.9% saline). The tubings were
led subcutaneously to emerge at the base of the neck; they were
then threaded through a thin wire spring (PGC Scientific Corp.,
Rockville, Maryland, USA), 20 cm long to protect the tubing.
After surgery, the animals were housed in individual cages and
the tubings were passed through the top of the cage to be
connected to 1 ml plastic syringes with a 23-gauge hypodermal
needle. Experiments were performed at least 4 hr after comple-
tion of surgery while the rats were awake, unrestrained, and
undisturbed, with an ambient temperature of 20 to 22°C. Blood
pressure and heart rate were measured before and immediately
after bolus injection of 0.1 ml of normal saline containing 10, 30,
100 and 300 ng of NE (Levophed bitartrate, Winthrop Labora-
tory, New York, New York, USA). Five to 10 mm separated
the injection of the various doses to allow the return of blood
pressure and heart rate to the preinjection levels. The pressor
response to 3, 10, 30 and 100 ng of angiotensin II (Sigma
Pharmaceutical, St. Louis, Missouri, USA) was evaluated also
in CRF-PTX and CRF-sham PTX animals.
Blood pressure was measured directly via the arterial cathe-
ter which was connected to a pressure transducer (P-bOO B,
Narco Bio-Systems, Houston, Texas, USA) and strain gauge
amplifier and recorder (MK-III, Narco Bio-Systems). The mean
arterial pressure (MAP) was calculated as the sum of diastolic
blood pressure and one-third of pulse pressure. Heart rate was
determined using the fluctuation of arterial blood pressure to
trigger a tachometer (Biotachometer, Coupler Type 7302,
Narco Bio-Systems).
The effects of increasing concentration of NE on the perfu-
sion pressure in isolated hind limb preparation was studied in
seven control, five CRF-sham PTX, and five CRF-PTX rats.
These are different animals than those used in the in vivo
studies. After anesthesia with sodium pentobarbital as de-
scribed above, the rats were prepared for hind limb perfusion
according to the method of Folkow et al [14]. The hind limbs
were perfused with oxygenated Tyrode solution (95% 02 and
5% C02, at 37°C, containing 2% (w/v) of an artificial colloid
(Ficol 70, Sigma Chemical Co). The perfusion pump (Harvard
peristaltic pump, Harvard Apparatus, Millis, Massachusetts,
USA) was adjusted to deliver 10 to 11 ml of perfusate/100 g of
tissue/mm. Perfusion pressure was measured by P-bOO B
pressure transducer connected to MK-III recorder (Narco
Bio-Systems, Houston, Texas, USA). Serum calcium was
determined by an atomic absorption spectrophotometer
(Perkin-Elmer Co., Model 503 Instrument Division, Norwalk,
Connecticut, USA), and serum creatinine by Technicon
autoanalyzer (Technicon Instrumentation Co., Tarrytown,
New York, USA). Statistical evaluation of the data was per-
formed by analysis of variance and by unpaired Student's t test.
Results
Table 1 presents the data on body wt, MAP, heart rate, and
serum concentrations of calcium and creatinine in control,
CRF-sham PTX rats with and without treatment with indometh-
acm, and CRF-PTX animals. The nephrectomy procedure was
successful in producing CRF, as evidenced by the threefold rise
in the serum levels of creatinine. There were no significant
differences in body wt, in serum concentrations of calcium, and
in heart rate among the various groups of animals. Baseline
MAP was significantly higher (P < 0.01) in both CRF-sham
PTX and CRF-PTX rats than control animals, Treatment with
indomethacin did not produce significant changes in MAP in
control or CRF-sham PTX rats.
The effects of the administration of NE on MAP and heart
rate are shown in Figure 1. The increments in MAP in CRF-
sham PTX rats were significantly (P < 0.01) less than in control
and CRF-PTX animals. Treatment of CRF-sham PTX rats with
indomethacin normalized the response to NE. It should be
emphasized that treatment of control rats with indomethacin
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Fig. 1. Relationship between the change in mean arterial pressure and
heart rate and the injected dose of norepinephrine in control, CRF-
sham PTX with and without treatment with indomeihacin, and in
CRF-PTX rats. Data obtained from normal rats treated with indometh-
acm are not included for clarity; the increment in mean arterial pressure
for the four NE doses were 14 1.4, 26 2.9, 43 2.5, and 52 4.0
mm Hg, respectively. These are not different from those in normal rats
without indomethacin treatment. Symbols are: •, control; •, CRF-
PTX; A, CRF-sham PTX; , CRF-sham PTX with indomethacin.
Table 2. Increase in mean arterial pressure (MAP) during infusion of





Control 8 23 1.4 36 2.3 46 2.0 53 1.3
CRF-sham PTX 8 11 2.16 20 20b 26 24b 33 1.5k
CRF-PTX 4 17 4.4 26 22a 37 l.9 43 l2
Abbreviations are the same as in Table 1. Data represent increment in
MAP (mm Hg) and are expressed as mean SE.
a P < 0.005 and b P < 0.01 compared with controls.
P < 0.05 compared with CRF-sham PTX.
Norepinephrine, g
Fig. 2. Dose-response curves between perfusion pressure and norepi-
nephrine in hind limb preparation from control, CRF-PTX, and CRF-
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did not affect the response to NE. The decrements in heart rate
in CRF-sham PTX rats during NE were significantly (P < 0.01)
less than in control and CRF-PTX animals, and treatment of
CRF-sham PTX rats with indomethacin normalized the re-
sponse in heart rate. Similarly, the pressor response to angio-
tensin II was markedly and significantly (P < 0.01) blunted in
CRF-sham PTX rats, and was significantly improved, ap-
proaching control values, in CRF-PTX rats (Table 2).
The dose-response curves between NE and perfusion pres-
sure of the hind limb preparation are given in Figure 2. There
was a significant shift to the right in the dose-response curve in
CRF-sham PTX rats as compared to controls (P < 0.01) and
CRF-PTX (P < 0.05) animals, indicating a decreased sensitivity
to NE in CRF-sham PTX rats. There was no significant differ-
ence between the dose-response curves in the control and
CRF-PTX rats.
Discussion
The results of the present study show that CRF in the rat, as
in humans, is associated with reduced responsiveness to the
pressor effect to NE. The animals displayed similar abnormality
following the administration of another pressor agonist, angio-
tensin II. These observations demonstrate that the CRF-sham
PTX rats provide a good model for the evaluation of the
mechanisms of this abnormality.
Reduced responsiveness to NE has been observed in acute
[7] and chronic renal failure [8] with both being states of
secondary hyperparathyroidism [9—12, 15]. Also observed was
a significant (P < 0.01) inverse relationship between the
changes in MAP during NE administration and the blood levels
of PTH in patients with chronic renal insufficiency [16]. Finally,
treatment with PTH blunts the pressor effect of NE in rats [4].
All observations were consistent with the idea that the excess
blood levels of PTH plays an important role in the genesis of the
reduced pressor effect of NE in chronic renal failure. However,
these observations do not provide conclusive evidence that
factors other than excess PTH do not play an important role in
the blunted response to vasoconstrictor agonists in uremia.
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Data of the present study demonstrated that normocalcemic
CRF-PTX rats have normal pressor response to NE and pro-
vided strong evidence that the blunted response to NE is related
to excess PTH and not to other consequences of the uremic
state.
Several pieces of evidence indicate that excess PTH blunts
the pressor response to NE through the stimulation of the
production of vasodilating prostaglandins. Saglikes et al [6]
reported that the administration of PTH to normal rats was
associated with an increase in the urinary excretion of 6-keto-
PGF1a, and that the blunting effect of the hormone on the
pressor response to NE was abolished by indomethacin treat-
ment [4, 6]. Collins, Massry and Campese [16] found that
treatment of CRF patients with indomethacin improved or
normalized the pressor response to NE. The observation of the
present study that indomethacin normalized the pressor re-
sponse to NE in CRF-sham PTX rats provides additional
support for the role of prostaglandins in the genesis of this
derangement. The suggestion that PTH may enhance
prostaglandin synthesis derives support from certain available
information. It is well known that PTH acts as a calcium
ionophore and enhances calcium entry into, and content of,
many mammalian cells [17—21]. It has been shown that in-
creased calcium movement, induced by calcium ionophore
A23183, into platelets [221 and renal medulla [23] is associated
with prostaglandin synthesis, and this effect is mediated by
increased release of free arachidonic acid [23].
Studies from our laboratory [24, 25] and from others [26, 27]
have shown that PTH affects myocardial function and metabo-
lism. Prolonged treatment of rats with PTH is associated with a
decrease in cardiac output and blood pressure [25]. Theoreti-
cally, it is possible that the effect of PTH on the pressor
response to NE may be mediated by an effect of the hormone on
the heart rather than On the blood vessels directly. Our findings
in the isolated hind limb preparation indicate clearly that PTH
exerts a direct effect on the response of the peripheral blood
vessels to NE.
The physiologic significance of our observations is related to
the pathogenesis of some of the manifestations of the autonomic
nervous system dysfunction in patients with chronic renal
failure. These patients display significant orthostatic decrease
in blood pressure despite a marked rise in plasma levels of NE
[8]. It is likely that the blunted pressor response to NE plays a
major role in the genesis of this orthostatic hypotension.
Previous studies from our laboratory have shown that the
effect of PTH on the response to vasoconstrictor agonists in
normal rats is mediated by increased production of
prostaglandin [6]. Patients with chronic renal failure are found
to have an inverse relationship between the magnitude of the
reduced pressor response to NE and the blood levels of PTH
[161. Treatment with indomethacin improved or restored to
normal the vascular responsiveness to NE. All these data
provide support for the role of and the possible mechanism
through which excess PTH may underlie some of the abnormal-
ities in the function of the autonomic nervous system in uremia.
It could be argued also that this effect of PTH on the pressor
response to vasoconstrictor agonists may provide protection
against worsening of hypertension in states of chronic renal
failure. This possibility remains speculative at the present time.
Acknowledgments
The authors thank Ms. R. Boscia for technical assistance and Ms. P.
Kentor and J. Jiminez for clerical support.
This work was supported by Grant AM 29955 from the National
Institute of Arthritis, Diabetes and Digestive and Kidney Diseases. Dr.
Iseki was a fellow of the American Heart Association of the Greater
Los Angeles Affiliate and supported by Group Investigation Award
#520 1G9.
Reprint requests to Dr. S. G. Massry, Division of Nephrology,
University of Southern California, 1200 North State Street, Los
Angeles, California 90033 USA
References
I. PANG PKT, JANSSEN HF, YEE JA: Effects of synthetic parathyroid
hormone on vascular beds of dogs. Pharmacology 2 1:213—222, 1980
2. PANG PKT, TENNER TE, YEE JA, YANG M, JANSSEN HF:
Hypotensive action of parathyroid hormone preparations on rats
and dogs. Proc NatI Acad Sci 77:675—678, 1980
3. ELLIsON DH, MCCARRON DA: Structural prerequisites for the
hypotensive action of parathyroid hormone. Am J Physiol
246:F55l—F556, 1984
4. SAGLIKEs Y, CAMPESE VM, MASSRY SG: Mechanism of the
hypotensive action of the intact and aminoterminal fragment of
parathyroid hormone (PTH). Proc XVth Ann Mtg Am Soc Nephrol,
1982, p 83A
5. ELLISON DH, MCCARRON DA: Infusion of bovine parathyroid
hormone 1—34 attenuates the pressor response to angiotensin II in
spontaneously hypertensive rats. Clin Exp Hyperten 11:1637—1647,
1982
6. SAGLIKE5 Y, MASSEY SG, ISEKI K, NADLER JL, CAMPESE VM:
Effect of PTH on blood pressure and response to vasoconstrictor
agonists. Am J Physiol 248:F674—F681, 1985
7. LEvITAN D, MAssEY SG, ROMOFF MS, CAMPESE VM: Autonomic
nervous system dysfunction in patients with acute renal failure. Am
J Nephrol 2:213—220, 1982
CAMPESE VM, ROMOFF MS, LEVITAN D, LANE K, MASSRY SG:
Mechanisms of autonomic nervous system dysfunction in uremia.
Kidney mt 20:246—253, 1981
9. ROTH SI, MARSHALL RB: Pathology and ultrastructure of the
human parathyroid glands in chronic renal failure. Arch Intern Med
124:397—407, 1969
10. KATZ Al, HAMPERS CL, MERRILL JP: Secondary hyperpara-
thyroidism and renal osteodystrophy in chronic renal failure. Med-
icine 48:333—374, 1969
11. BERSON SA, YALOW RS: Parathyroid hormone in plasma in ade-
nomatous hyperparathyroidism, uremia, and bronchogenic carci-
noma. Science 154:907—909, 1966
12. MASSRY SG, COBURN JW, PEACOCK M, KLEEMAN CR: Turnover of
endogenous parathyroid hormone in uremic patients and those
undergoing hemodialysis. Trans Am Soc Artif Intern Organs
18:416—422, 1972
13. LEVI M, ELLIS MA, BERL T: Control of renal hemodynamics and
glomerular filtration rate in chronic hypercalcemia. Role of prosta-
glandins, renin-angiotensin system and calcium. J Clin Invest
71:1624—1632, 1983
14. FOLKOW B, HAUBACK M, LUNDGRENY Y, WEISS L: Background of
increased flow resistance and vascular reactivity in spontaneously
hypertensive rats. Acta Physiol Scand 80:93—106, 1970
15. MASSRY SG, ARIEFF Al, COBURN JW, PALMIERI U, KLEEMAN CR:
Divalent ion metabolism in patients with acute renal failure: studies
on the mechanism of hypocalcemia. Kidney tnt 5:437—445, 1974
16. COLLINS J, MASSRY SG, CAMPESE VM: Parathyroid hormone and
the altered vascular response to norepinephrine in uremia. Am J
Nephrol 5:110—113, 1985
17. BORLE AB: Calcium metabolism in Hela cells and the effect of
parathyroid hormone. J Cell Biol 36:567—582, 1968
18. CHAUSMER AB, SHERMAN BS, WALLACH 5: The effect of parathy-
roid hormone on hepatic cell transport of calcium. Endocrinology
90:663—672, 1972
19. MASSRY SG, COBURN JW, HARTENBOWER DL, SHINABERGER JH,
PTH and pressor response to norepinephrine 15
DEPALMA JR, CHAPMAN E, KLEEMAN CR: Mineral content of
human skin in uremia: effect of secondary hyperparathyroidism and
hemodialysis. Proc Eur Dial Transplant Assoc 7:146—150, 1970
20. BERKOW JW, FINE BS, ZIMMERMAN LE: Unusual ocular calcifi-
cation in hyperparathyroidism. Am J Ophthalmol 66:812—824, 1968
21. BOGIN E, MASSRY SG, HARARY I: Effect of parathyroid hormone
on rat heart cells. J Clin Invest 67:1215—1227, 1981
22. OELZ 0, KNAPP MR, ROBERT Li, OELZ R, SWEETMAN BJ, OATES
JA, REED WP: Calcium-dependent stimulation of thromboxane and
prostaglandin biosynthesis by ionophores. Adv Prostaglandins
Thromboxane Res 3:147—158, 1978
23. ZENSER TV, HERMAN CA, DAvis BB: Effects of calcium and
A23 187 on renal inner medullary prostaglandin E2 synthesis. Am J
Physiol 238:E371—E376, 1980
24. BOGIN E, LEVI J, HARARY I, MASSRY SG: Effects of parathyroid
hormone on oxidative phosphorylation of heart mitochondria.
Miner Electrolyte Metab 7:151—156, 1982
25. BACZYNSKI R, MASSRY SG, KOHAN R, MAGOTT M, SAGLIKES Y,
BRAUTBAR N: Effect of parathyroid hormone on myocardial energy
metabolism in the rat, Kidney mt 27:718—725, 1985
26. LHOSTE FT, DRUEKE SL, BOISSIER JR: Cardiac interaction be-
tween parathyroid hormone, alpha-adrenoreceptor, and verapamil
in the guinea-pig in vitro. Clin Exp Pharmacol Physiol 7:377—385,
1980
27. KAHOT Y, KLEIN KL, KAPLAN RA, SANBORN WG, KUROKAWA
K: Parathyroid hormone has a positive inotropic action in the rat.
Endocrinology 109:2252—2254, 1981
